Last reviewed · How we verify
Kenacort A,
At a glance
| Generic name | Kenacort A, |
|---|---|
| Also known as | miconaz gel |
| Sponsor | Jaylane kadry Ghonima |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- ALOPECIA
- FATIGUE
- Dermatitis
- NAUSEA
- NEUTROPENIA
- DIARRHEA
- NEUROPATHY
- EDEMA
- PAIN
- RASH
- ANEMIA
- CONSTIPATION
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenacort A, CI brief — competitive landscape report
- Kenacort A, updates RSS · CI watch RSS
- Jaylane kadry Ghonima portfolio CI